Table 3 Cancer-specific survival according to risk stratification
Risk group | Median time, months (95% CI) | 2-year rate, % (95% CI) | 5-year rate, % (95% CI) | Hazard ratio (95% CI) | P-value |
|---|---|---|---|---|---|
Training/validation cohort (n = 401) | |||||
Low-risk (n = 194) | 74.6 (58.3-NA) | 81.6 (76.0–87.6) | 58.1 (49.1–68.6) | 1 | |
Intermediate-risk (n = 165) | 19.0 (16.6–23.7) | 39.9 (32.4–49.1) | 10.3 (4.8–22.2) | 3.901 (2.826–5.384) | < 0.001* |
High-risk (n = 42) | 7.0 (4.4–9.9) | NA | NA | 2.794 (1.606–4.863) | < 0.001† |
Test cohort (n = 649) | |||||
Low-risk (n = 345) | 73.0 (60.0–89.0) | 82.5 (78.6–86.7) | 54.1 (48.4–60.4) | 1 | |
Intermediate-risk (n = 251) | 28.0 (24.0–33.0) | 55.5 (49.6–62.1) | 18.5 (13.3–25.8) | 2.496 (1.980–3.146) | < 0.001* |
High-risk (n = 53) | 11.0 (7.0–13.0) | 7.8 (3.0–19.9) | 0.0 (NA) | 3.509 (2.149–5.728) | < 0.001† |